Immunic (IMUX)
(Delayed Data from NSDQ)
$1.21 USD
-0.06 (-4.72%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $1.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 81 - 100 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838''s Safety and Efficacy Profile Continues to Impress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838 CALLIPER Trial Initiation; ECTRIMS Data Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838 Prospects in MS Appear Solid - Reiterate Buy on Program & Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Merck''s Molnupiravir Data Supports Developmemt Path for IMU-838 in COVID
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 CALLIPER Study of IMU-838 Enrolls its First Progressive MS Patient
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Program Poised to Start; Lowering PT to $25 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update - Programs On Track & IMU-935 Data Likely to Boost the Stock
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Pipeline Execution in H2:21 Setting Up for Multiple Catalysts in 2022-23
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Immunic Provides Two Reasons Why IMU-935 (RORyt) Should Be on Your Radar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on IMU-935 at Virtual R&D Event; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Virtual R&D Day Introduces IMU-935''s Potential in Autoimmune Diseases, Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z